AI and Cancer Research ── Lymphoma ── 2026-11-14
Lymphoma: treatment, trials and AI
- Abstract
PURPOSE: To assess if AI-assisted segmentation on [ 18 F]FDG PET/CT significantly reduces time in quantifying Total Metabolic Tumor Volume (TMTV) and the greatest distance between two lesions (Dmax) in Large B-cell lymphoma (LBCL) patients. METHODS: A retrospective study at two institutions included 56 LBCL patients (Ann-Arbor staging: 14% with no disease, 25% stage I-II, 61% stage III-IV). Two methods were compared: AI-assisted segmentation (Pionus ® v1.1.0, PAIRE, Paris) automatically identified lesions with expert correction of AI errors, while expert-led segmentation was fully manual. Both methods used a 41% SUVmax threshold. RESULTS: AI-assisted segmentation was 41% faster, saving an average of 104 s per patient (152 ± 134 s vs. 255 ± 270 s, p < 0.001), with time saved correlating with TMTV (r = 0.67, p < 0.001). No significant differences in TMTV or Dmax were found between methods. Intraclass correlation coefficients were high for both TMTV (0.91 and 0.95) and Dmax (0.97 and 0.95), with strong inter-reader agreement. CONCLUSION: AI-assisted segmentation significantly reduces time for TMTV and Dmax measurement in LBCL patients, especially in patients with high tumor burden, while maintaining high reliability and inter-reader agreement. The impact on the integrated clinical workflow has yet to be assessed.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Micheletti V, Marchal É, Gambiez M, Dercle L, Meyer ME, Palard-Novello X, et al. AI-assisted [18F]FDG PET/CT quantification: a time-saving approach in large B-cell lymphoma?. EJNMMI Phys. 2026 Aug 16;13(1):106. doi:10.1186/s40658-026-00923-y. PMID: 43015420.Checked: Abstract only